MOESM2 of A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum

Additional file 2: Figure S1. Overview of the design of the two clinical vaccine studies from which the serum samples have been derived

MOESM2 of The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity

Additional file 2. M1 versus M2: Scatterplot comparing M1 and M2 opsonization frequency and intensity

Liver function tests.

<p>Levels of (<b>A</b>) ALT (alanine aminotransferase), (<b>B</b>) AST (aspartate aminotransferase) and (<b>C</b>) total bilirubin versus study day for each of the six subjects. The horizontal dotted line indicates normal range. Abbreviations: ULN: upper limit of normal; LLN: lower limit of normal).</p

Clinical adverse events attributed to malaria infection by severity.

<p>The majority of clinical AEs were mild with only 11 moderate and 5 severe clinical AEs attributable to malaria infection.</p

Distribution of infected mosquitoes per day of feed in each study cohort according to inoculation method

<p>Distribution of infected mosquitoes per day of feed in each study cohort according to inoculation method</p

Laboratory parameters recorded as adverse events.

<p>All clinically significantly abnormal laboratory parameters are represented according to their severity. All were attributed to malaria infection. There were no significantly abnormal laboratory parameters recorded as AEs attributable to other causes. Of the 25 laboratory parameters that were recorded as AEs, 15 were abnormalities of LFTs, i.e. either an elevation of ALT or AST. The majority of laboratory AEs were moderate in severity with 2 mild and 9 severe. Abbreviations: LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine amino transferase.</p

Parasitemia and gametocytemia pre and post antimalarial treatment.

<p>(<b>A</b>) Parasitemia as determined by qPCR of the 18S rDNA target. (<b>B</b>) Estimate of gametocytemia as determined by <i>pvs25</i> qRT-PCR. Closed lines or “pre” depicts subjects from first parasitemia detection to treatment with artemether/lumefantrine on Day 14 as per protocol. Dashed lines or “post” represents clearance of the parasitemia following treatment. Day represents study day with inoculation occurring on Day 0.</p

Most frequent adverse events (AEs) reported in the study due to all causes.

<p>AE are schematized according to their causality and severity. Fever was the most common AE reported (n = 22). The majority of AEs reported were mild. Only 14 severe AEs were reported and all were attributed to malaria. Abbreviations: ALT: alanine amino transferase; AST: aspartate aminotransferase.</p

Structures observed on mosquito midguts.

<p><b>(A)</b> and <b>(B)</b> Oocyts observed on midguts of mosquitoes fed with <i>P</i>. <i>vivax</i> infected blood. <b>(C)</b> and <b>(D)</b> Other ovoid structures observed on midguts of mosquitoes fed with <i>P</i>. <i>vivax</i> infected blood. <b>(E)</b> and <b>(F)</b> Midguts of mosquitoes fed with non-infected blood (negative control). No structures were present on the mosquito midgut represented in panel E. Panel F illustrates ovoid structures observed on the mosquito midguts of some negative controls. Magnification: 20x in panels A, C, D and F; 10x in panel B; 4x in panel E.</p

Study flow diagram.

<p>Study flow diagram.</p